These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29635472)

  • 41. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ; Zhao M; Andes DR
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting the clinical efficacy of generic formulations of ceftriaxone.
    Schito GC; Keenan MH
    J Chemother; 2005 Sep; 17 Suppl 2():33-40. PubMed ID: 16315582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis.
    Wang YK; Wu YE; Li X; Tian LY; Khan MW; Tang BH; Shi HY; Zheng Y; Hao GX; van den Anker J; You DP; Zhao W
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Sweeney D; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Feb; 87(2):121-128. PubMed ID: 27890418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
    Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model.
    Atahan E; Gul M; Ergun Y; Eroglu E
    Eur J Vasc Endovasc Surg; 2007 Aug; 34(2):182-7. PubMed ID: 17481929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R; Rybak MJ
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):539-46. PubMed ID: 14596973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
    Maglio D; Kuti JL; Nicolau DP
    Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
    Foerster S; Unemo M; Hathaway LJ; Low N; Althaus CL
    BMC Microbiol; 2016 Sep; 16():216. PubMed ID: 27639378
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
    Abbott IJ; van Gorp E; Cottingham H; Macesic N; Wallis SC; Roberts JA; Meletiadis J; Peleg AY
    J Antimicrob Chemother; 2023 Feb; 78(2):397-410. PubMed ID: 36473954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal Cefazolin Prophylactic Dosing for Bariatric Surgery: No Need for Higher Doses or Intraoperative Redosing.
    Chen X; Brathwaite CE; Barkan A; Hall K; Chu G; Cherasard P; Wang S; Nicolau DP; Islam S; Cunha BA
    Obes Surg; 2017 Mar; 27(3):626-629. PubMed ID: 27520693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency of pharmacological target attainment with flucloxacillin and cefazolin in invasive methicillin-susceptible Staphylococcus aureus infection: a prospective cohort study in hospitalized patients.
    Campbell PO; Chin PKL; Dalton SC; Metcalf SCL; Douglas NM; Chambers ST
    Int J Antimicrob Agents; 2023 Jan; 61(1):106695. PubMed ID: 36464153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
    Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
    Hamada Y; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cooperation of pharmacologic-dose ascorbate with ceftriaxone against Staphylococcus aureus through bactericidal synergy and enhanced macrophage killing activity.
    Wirapakorn C; Singkham-In U; Taratummarat S; Surawut S; Visitchanakun P; Chatsuwan T; Leelahavanichkul A
    Asian Pac J Allergy Immunol; 2019 Jun; 37(2):94-101. PubMed ID: 30118242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.